Loading
Virus-based Gene Therapy Research / Respiratory Viral Infections Research · Journal article
Tropical Diseases Travel Medicine and Vaccines · August 8, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes current knowledge of RSV epidemiology, clinical presentation, and the emerging pharmacologic prevention landscape, including three FDA-approved vaccines (Arexvy, Abrysvo, mRESVIA) and monoclonal antibodies (Nirsevimab, Clesrovimab). It provides a structured overview for understanding RSV's public health burden and prevention options but does not present new trial data or comparative efficacy evidence.
Narrative review. Infants and children, with emphasis on vulnerable populations; global perspective.
Three RSV vaccines have received FDA approval: Arexvy, Abrysvo, and mRESVIA Monoclonal antibodies Nirsevimab and Clesrovimab prevent severe RSV disease and are recommended for infants RSV exhibits distinct seasonal trends that vary by geographic location and climate zone
No efficacy, effectiveness, or safety data reported for any vaccine or monoclonal antibody
Clinicians and policymakers should recognize FDA-approved RSV vaccines and monoclonal antibodies as available prevention options, particularly for high-risk infants. Seasonal patterns should inform local immunization program scheduling, though specific efficacy data and comparative effectiveness are not provided in this review.
A narrative review summarizing RSV pathogenesis, epidemiology, clinical features, and the landscape of approved vaccines and monoclonal antibodies; provides synthesis for clinical decision-making but not original trial evidence.
As stated by the source record.
Clinicians and policymakers should recognize FDA-approved RSV vaccines and monoclonal antibodies as available prevention options, particularly for high-risk infants. Seasonal patterns should inform local immunization program scheduling, though specific efficacy data and comparative effectiveness are not provided in this review.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Respiratory Syncytial Virus (RSV) is a formidable respiratory pathogen that particularly affects infants and children. RSV presents with diverse clinical severity, most often causing mild upper airway symptoms but sometimes progressing to severe and potentially fatal lower respiratory tract disease. This virus has a major global public health impact and places a substantial strain on healthcare systems. RSV exhibits distinct seasonal trends that vary across geographic locations and climate zones, and recognizing these patterns and their determinants is essential for policymakers to schedule RSV immunization programs effectively. Increasing attention has been directed toward the evolving landscape of RSV vaccines, particularly regarding their potential to prevent infection and reduce disease severity, especially among vulnerable populations. Until now, three RSV vaccines, Arexvy, Abrysvo, and mRESVIA, have received approval from the FDA. In addition, monoclonal antibodies such as Nirsevimab and Clesrovimab prevent severe RSV disease and are recommended for infants. Given the significant global impact of RSV, this narrative review addresses its multifaceted aspects, including epidemiology and global impact, clinical manifestations, therapeutic strategies, vaccine development, and its emerging potential as an oncolytic agent.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.